The FDA should end the Novavax vaccine delay
Tuesday, May 24, 2022
The long-anticipated Novavax vaccine, an alternative to current messenger RNA vaccines against COVID-19, submitted for emergency use authorization to the FDA at the end of January. Without much explanation, the FDA has shown little sign of action and it only recently scheduled a tentative June vaccine advisory committee meeting for discussion, writes Ray W. Shepherd, MD, in the Richmond Times-Dispatch.
|
|
Email to a Friend